| 000 | 00965 a2200265 4500 | ||
|---|---|---|---|
| 005 | 20250514075220.0 | ||
| 264 | 0 | _c20031223 | |
| 008 | 200312s 0 0 eng d | ||
| 022 | _a1388-9842 | ||
| 024 | 7 |
_a10.1016/s1388-9842(03)00045-x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRichards, A Mark | |
| 245 | 0 | 0 |
_aVasopeptidase inhibitors for heart failure: where do we go from here? _h[electronic resource] |
| 260 |
_bEuropean journal of heart failure _cAug 2003 |
||
| 300 |
_a411-3 p. _bdigital |
||
| 500 | _aPublication Type: Editorial | ||
| 650 | 0 | 4 |
_aHeart Failure _xblood |
| 650 | 0 | 4 |
_aHemodynamics _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aMetalloendopeptidases _xpharmacology |
| 650 | 0 | 4 |
_aPyridines _xpharmacology |
| 650 | 0 | 4 |
_aThiazepines _xpharmacology |
| 773 | 0 |
_tEuropean journal of heart failure _gvol. 5 _gno. 4 _gp. 411-3 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s1388-9842(03)00045-x _zAvailable from publisher's website |
| 999 |
_c12694728 _d12694728 |
||